Patents by Inventor Pritom Shah
Pritom Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11453666Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: March 20, 2020Date of Patent: September 27, 2022Assignee: Cancer Research Technology LimitedInventors: Martin Lee Stockley, Ellen Catherine Macdonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
-
Publication number: 20200283435Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: March 20, 2020Publication date: September 10, 2020Inventors: Martin Lee Stockley, Ellen Catherine Macdonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
-
Patent number: 10654846Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: February 4, 2016Date of Patent: May 19, 2020Assignee: Cancer Research Technology LimitedInventors: Martin Lee Stockley, Ellen Catherine MacDonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
-
Patent number: 10428061Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: October 25, 2018Date of Patent: October 1, 2019Assignee: Cancer Research Technology LimitedInventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Publication number: 20190062324Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Inventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Patent number: 10138230Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: GrantFiled: February 4, 2016Date of Patent: November 27, 2018Assignee: Cancer Research Technology LimitedInventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
-
Publication number: 20180022742Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: February 4, 2016Publication date: January 25, 2018Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Francesca BLUM, James Lindsay CARR, Pritom SHAH, Maria DEL MAR JIMENEZ QUESADA, Irene FARRE GUTIERREZ
-
Publication number: 20180016274Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.Type: ApplicationFiled: February 4, 2016Publication date: January 18, 2018Applicant: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Martin Lee STOCKLEY, Ellen Catherine MACDONALD, Pritom SHAH, Allan JORDAN, James HITCHIN, Niall HAMILTON
-
Publication number: 20090274655Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.Type: ApplicationFiled: November 15, 2007Publication date: November 5, 2009Inventors: Richard Martin Grimes, Charles David Hartley, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
-
Publication number: 20090136448Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.Type: ApplicationFiled: December 20, 2006Publication date: May 28, 2009Inventors: John Andrew Corfield, Richard Martin Grimes, David Harrison, Charles David Hartley, Peter David Howes, Joelle Le, Malcolm Lees Meeson, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
-
Patent number: 7304087Abstract: Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C1-6alkyl; J represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.Type: GrantFiled: October 22, 2003Date of Patent: December 4, 2007Assignee: Glaxo Group LimitedInventors: David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Pritom Shah, Martin John Slater
-
Patent number: 7259163Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.Type: GrantFiled: October 30, 2002Date of Patent: August 21, 2007Assignee: Glaxo Group LimitedInventors: Gianpaolo Bravi, Rossella Guidetti, David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Victoria Lucy Helen Lovegrove, Pritom Shah, Martin John Slater, Katrina Jane Wareing
-
Publication number: 20070167507Abstract: Novel antiviral compounds of Formula (I): wherein: A represents hydroxy; R1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, C1-6alkyl or —C5-9cycloalkyl, each of which may be optionally substituted; R2 represents substituted phenyl, or —(CH2)nC5-7cycloalkyl optionally substituted on the cycloalkyl; R3 represents heterocyclyl or heteroaryl; optionally substituted phenyl or optionally substituted —C1-6alkyl; R4 represents hydrogen; and salts, solvates and esters thereof processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.Type: ApplicationFiled: March 22, 2005Publication date: July 19, 2007Applicants: GLAXO GROUP LIMITED, SMITHKLINE BEECHAM CORPORATIONInventors: Gianpaolo Bravi, John Corfield, Richard Grimes, Rossella Guidetti, Victoria Lucy Lovegrove, Jacqueline Mordaunt, Pritom Shah, Martin Slater
-
Publication number: 20050043545Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 5-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.Type: ApplicationFiled: October 30, 2002Publication date: February 24, 2005Inventors: Gianpalol Bravi, Helene Goodland, David Haigh, Charles Hartley, Victoria Lovegrove, Pritom Shah, Martin Slater
-
Publication number: 20050043390Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6-alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.Type: ApplicationFiled: October 30, 2002Publication date: February 24, 2005Inventors: Gianpaolo Bravi, Rossella Guidetti, David Haigh, Charles Hartley, Peter Howes, Deborah Jackson, Victoria Lovegrove, Pritom Shah, Martin Slater, Katrina Wareing
-
Publication number: 20050009873Abstract: Novel anti-viral agents of Formula (I) wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; D represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; E represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.Type: ApplicationFiled: October 30, 2002Publication date: January 13, 2005Inventors: Gianpaolo Bravi, Peter Howes, Victoria Lovegrove, Pritom Shah, Martin Slater
-
Patent number: 6215002Abstract: There are described according to the invention, processes for making compounds of formula (XXVIII)3 (relative stereochemistry indicated), wherein P2 is as defined in the specification.Type: GrantFiled: March 3, 2000Date of Patent: April 10, 2001Assignee: Glaxo Wellcome Inc.Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Inglis, Martin Redpath Johnson, Simon John Fawcett MacDonald, Pritom Shah, Robin Andrew Smith
-
Patent number: 6177425Abstract: According to the invention there are provided Hexahydro-Pyrrolo[3,4-b]pyrrol-2-one compounds of formula (1), (relative stereochemistry indicated), wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (1) are useful inter alia in the treatment or chronic bronchitis.Type: GrantFiled: May 5, 2000Date of Patent: January 23, 2001Assignee: Glaxo Wellcome Inc.Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Adam Inglis, Martin Redpath Johnson, Simon John Fawcett MacDonald, Pritom Shah
-
Patent number: 5994344Abstract: There are described according to the invention compounds of formula (I) (relative stereochemistry indicated), wherein R.sub.1, R.sub.2, R.sub.3 and X are as defined in the specification, together with processes for preparing them, compositions containing them and their use as pharmaceuticals. Compounds of formula (I) are indicated inter alia for the treatment of chronic bronchitis.Type: GrantFiled: September 25, 1998Date of Patent: November 30, 1999Assignee: Glaxo Wellcome Inc.Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Inglis, Martin Redpath Johnson, Simon John Fawcett Macdonald, Pritom Shah, Robin Andrew Smith
-
Patent number: 5641775Abstract: The invention relates to 3-phenylureido-1,5-benzodiazepine-diones of formula (I) ##STR1## and pharmaceutically acceptable salts and solvates thereof, and to their use as gastrin/CCK-B antagonists.Type: GrantFiled: October 23, 1995Date of Patent: June 24, 1997Assignee: Glaxo SpAInventors: Harry Finch, David Gordon Trist, Aldo Feriani, Giorgio Tarzia, Pritom Shah